Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Eli Lilly & Company
Teriparatide relies on more than BMD to reduce fracture risk in osteoporosis, new data show
October 26th, 2005
A new data analysis of the Fracture Prevention Trial showed that increases in bone mineral density (BMD) account for 30-40% of the vertebral fracture risk reduction seen with teriparatide. This work is important because it helps to explain how teriparatide works to prevent fractures. While BMD is a standard measurement used to assess osteoporosis treatment efficacy, the ability of teriparatide to reduce vertebral fracture risk was due in part to BMD, but primarily to improvements in other non-BMD components of bone strength. Understanding these aspects of bone strength will require additional research. These data, presented at the 27th Annual Meeting...
Source: Elder Law Weekly (2005-10-26)
|
